Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

So what

Beyond the general rally in the biotech sector caused by the surprise election of Donald Trump, shares of Regeneron reacted favorably to the release of the company's third-quarter earnings. Here's a look at a few of the highlights from the report:

Revenue jumped 7% to $1.22 billion.

Non-GAAP earnings grew 32% to $3.13 per share, which was far ahead of $2.71 that Wall Street had projected.

Sales of top-selling eye disease drug Eylea rose 16% year over year to $854 million.

Regeneron's partner Sanofi(NYSE:SNY) reported that sales of its cholesterol-busting drug Praluent jumped to $38 million in the quarter. That was more than it sold in the first and second quarters of 2016 combined.

In addition to earnings, the company also had two other positive announcements to share with investors in November.

First, CEO Leonard Schleifer and Chief Scientific Officer George Yancopoulos were named National Life Sciences Entrepreneurs of the Year by Ernst & Young.

Second, an independent Data Monitoring Committee (DMC) recommended that the company's ODYSSEY OUTCOMES trial should continue as planned. This trial is designed to measure the change in cardiovascular events in high-risk patients who use Praluent. This recommendation was made in response to the DMC performing a planned interim analysis of the trial.

All in all, it was a month filled with positive news, so it is no surprise to see that shares rose so much during the month. That's especially true when you remember that the stock dropped by double digits in October.

Now what

Looking ahead, there are plenty of upcoming events for shareholders to look forward to.

First, Regeneron and Sanofi are expecting a Food and Drug Administration decision on their monthly dosing option for Praluent on Jan. 24, 2017, as well as data from the ODYSSEY OUTCOMES trial in late 2017. If the trial shows that using Praluent helps to lower the risk of cardiovascular events, then sales will likely surge.

Second, the two companies should also receive a go/no-go decision from the agency about Dupixent (dupilumab), an atopic dermatitis drug, in late March. This drug is believed to hold blockbuster potential, so a positive decision would likely send shares soaring.

Finally, investors can look forward to Regeneron and Sanofi announcing their resubmission of sarilumab in the coming months as a hopeful treatment of rheumatoid arthritis. The FDA had previously rejected the two companies' application due to manufacturing issues that were identified in one of Sanofi's plants in France. Fixing the issues and resubmitted the drug for regulatory review remain a top priority for both companies.

Overall, the long-term bull case for Regeneron continues to look strong. With shares currently down more than 30% from their 52-week highs, right now could be a great time to consider joining me as a shareholder.

Brian Feroldi owns shares of Regeneron Pharmaceuticals. Like this article? Follow him on Twitter where he goes by the handle @Longtermmindset or connect with him on LinkedIn to see more articles like this.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Author

Brian Feroldi has been covering the healthcare and technology industries for the Motley Fool since 2015. Brian's investing goal is to find the highest quality companies that he can find, buy them, and then to sit back and let compounding work its magic. See all of his articles here and make sure you follow him on Twitter.
Follow @brianferoldi